This site is intended for health professionals only

Stroke risk with ranibizumab

teaser

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Genentech Inc has sent a letter to doctors in the USA, advising them of the results of an interim analysis of a trial of ranibizumab (Lucentis). According to these preliminary results, 1.2% of patients given a 0.5mg dose of the drug suffered a stroke, compared with 0.3% of those given a 0.3mg dose.

According to a company spokesperson, these findings are consistent with data from previous trials. In addition, it appears that patients who had a previous stroke are at greater risk of another stroke.






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x